Review / clinical study · PMID 41935312
Migraine in pediatric population: the role of biochemical markers including VIP — VialBase Research
VIP is a biochemical biomarker for migraine in pediatric populations
Last updated · 2026 · Multiple authors · Journal of Headache and Pain
Key findings
- VIP is a biochemical biomarker for migraine in pediatric populations
- VIP alongside CGRP and PACAP38 are key neuropeptides in migraine pathophysiology
- Neuropeptide levels may predict migraine severity and treatment response
- VIP released from trigeminal and parasympathetic nerve fibers during migraine attacks
PMID 41935312 — VIP as Migraine Biomarker
Compound: VIP Citation: J Headache Pain. 2026;27(1):96. doi:10.1186/s10194-026-02344-9
Summary
Examines the role of biochemical markers including VIP, CGRP, and PACAP38 in pediatric migraine. VIP is released from trigeminal and parasympathetic nerve fibers during migraine attacks and may serve as a biomarker for diagnosis and treatment monitoring.
Relevance to VIP
Positions VIP as a clinically relevant biomarker in headache medicine. VIP’s dual role as both a potential therapeutic agent (vasoactive, anti-inflammatory) and a pathophysiological marker in migraine reflects its complex neurovascular regulatory functions.
See Also
- Parent compound: VIP